Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
HD$360.38+4.94(+1.39%)Three Days, 36 Hands-On Workshop Sessions and HGTV's Biggest Stars: Here's What's Happening Each Day at the First-Ever DIY CON November 6-88:33:00 AM ETMCD$281.70+1.48(+0.53%)McDonald's Q3: 11% EPS Growth And A 50% Operating Margin Say The Sell-Off Was A Mistake8:30:51 AM ETTMO$711.10+4.94(+0.70%)Thermo Fisher Scientific Introduces Value-Priced Thermo Scientific™ AmpSure™ Universal qPCR Master Mixes Without Compromising Performance8:30:16 AM ETAAPL$353.80+4.29(+1.23%)Apple Stock Is Up 22%, but 1 Slowing Business Could Test That Valuation8:30:00 AM ETBRK-A$881,000.00+11,699.24(+1.35%)Two in three US-listed companies pay no dividend, a census of SEC filings finds8:30:00 AM ETTEAD$0.19-0.08(-29.63%)Ad platform Teads misses Q3 revenue estimates; suspends guidance8:29:01 AM ETC$126.60+1.83(+1.47%)UPDATE 6-Oil rises as investors weigh uncertainties around Iran war8:27:07 AM ETMRNA$257.50-0.84(-0.33%)Moderna, Humana and Elanco Earnings Previews: What Investors Should Watch8:18:32 AM ETQCOM$153.90-19.29(-11.14%)Qualcomm: The AI Boom's Biggest Casualty8:18:20 AM ETAMD$465.00-23.78(-4.87%)AMD: The Bigger Earnings Opportunity Starts In 20278:17:47 AM ETV$439.98+3.39(+0.78%)Visa Just Raised Its Dividend 16%. Is It a Better Buy Than Mastercard?8:17:32 AM ETCVS$80.84+0.85(+1.06%)RPT-BREAKINGVIEWS-CVS’s problem: investors trust the warning label8:16:38 AM ETCOP$138.87+1.93(+1.41%)STAK Energy Signs Long-Term Agreement to Bring North Slope Natural Gas to Market8:15:00 AM ETMU$758.01-37.45(-4.71%)Is Micron stock a Buy after crashing below $800?8:13:57 AM ETGOOG$290.18+2.88(+1.00%)Meta Paid 1.4 Times What Alphabet Did to Borrow in Euros8:08:00 AM ETCOP$138.87+1.93(+1.41%)ConocoPhillips Profit Rises as Oil Prices Climb8:06:00 AM ETTCPC$4.30-0.08(-1.83%)BlackRock TCP Capital Corp. Announces Third Quarter 2026 Financial Results Including Net Investment Income of $0.16 Per Share; Declares a Fourth Quarter Dividend of $0.17 Per Share8:05:07 AM ETINTC$57.02-1.26(-2.16%)Intel: I Warned Before The 40% Crash, Now I'm Bullish (Rating Upgrade)8:05:00 AM ETASML$1,458.36-37.78(-2.53%)Could $10,000 Invested in ASML Set You Up for Life?8:05:00 AM ETAVGO$317.28-8.42(-2.59%)Broadcom Stock Could Be Approaching a Major Turning Point. Here's the Price Target8:03:07 AM ETVZ$46.65+0.48(+1.04%)Verizon Makes the Holidays Simple with Our Best Deals and Rewards Just for Being a Customer8:01:25 AM ETSHEL$102.67+0.81(+0.80%)Transaction in Own Shares8:00:53 AM ETIBM$255.90+1.58(+0.62%)IBM, AMD, Oak Ridge National Laboratory launch quantum error correction platform8:00:48 AM ETMETA$635.54+5.54(+0.88%)Voters rejected AI data centers over resource concerns. Here's why measuring water usage is hard8:00:01 AM ET

PVLA · NASDAQ

Palvella Therapeutics, Inc.

$157.00 -5.95 (-3.65%)

Company overview

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients with serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), which is in a Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as a Phase 2 clinical trial to treat cutaneous venous malformations. The company also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. Palvella Therapeutics is based in Wayne, Pennsylvania.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$2.3B
Employees
14
Headquarters
Wayne, PA
Website
palvellatx.com
CEO
Wesley H. Kaupinen
Listed
January 2, 2015
P/E
-37.65
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
$0.00
Operating income
-$45.6M
EBITDA
-$33.6M
Net income
-$49.3M
EPS
-$4.17
Total assets
$264M
Total debt
$584,000
Earnings yield
-2.66%

Price chart

97.45114.66131.88149.09166.30
PVLA 1D NASDAQ O155.00H163.75L147.25C162.95+10.02 (+6.55%)Vol345.22K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
PVLAPalvella Therapeutics, Inc. Stock news Palvella Therapeutics Q3 net loss widens on higher costs Reuters
PVLAPalvella Therapeutics, Inc. Press release Palvella Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update GlobeNewswire
PVLAPalvella Therapeutics, Inc. Stock news Palvella Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update GlobeNewswire
PVLAPalvella Therapeutics, Inc. Press release Palvella Therapeutics to Participate in the Stifel 2026 Healthcare Conference GlobeNewswire
PVLAPalvella Therapeutics, Inc. Stock news Palvella Therapeutics to Participate in the Stifel 2026 Healthcare Conference GlobeNewswire
PVLAPalvella Therapeutics, Inc. Press release Palvella Therapeutics to Host Third Quarter 2026 Financial Results and Corporate Update Conference Call on November 5, 2026 GlobeNewswire
PVLAPalvella Therapeutics, Inc. Press release Palvella Announces FDA Acceptance and Priority Review of QTORIN™ Rapamycin NDA; February 28, 2027 PDUFA Target Action Date Set GlobeNewswire
PVLAPalvella Therapeutics, Inc. Stock news Palvella Therapeutics Eyes QTORIN Launch as Rare-Disease Pipeline Expands MarketBeat
PVLAPalvella Therapeutics, Inc. Press release Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual Conference GlobeNewswire
PVLAPalvella Therapeutics, Inc. Press release Palvella Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference GlobeNewswire
PVLAPalvella Therapeutics, Inc. Stock news Amazon To $310? Here Are 10 Top Analyst Forecasts For Monday Benzinga
PVLAPalvella Therapeutics, Inc. Press release Palvella Therapeutics Announces Three Poster Presentations Highlighting New Data in Microcystic Lymphatic Malformations and DSAP at Fall Clinical Dermatology 2026 GlobeNewswire
PVLAPalvella Therapeutics, Inc. Stock news Palvella Therapeutics: FDA Handholding Makes The Regulatory Story Stronger Seeking Alpha
PVLAPalvella Therapeutics, Inc. Press release U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations GlobeNewswire
PVLAPalvella Therapeutics, Inc. Press release Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth Business Wire
PVLAPalvella Therapeutics, Inc. Press release Palvella Therapeutics Appoints James R. Treat, M.D. GlobeNewswire
PVLAPalvella Therapeutics, Inc. Press release Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences GlobeNewswire
PVLAPalvella Therapeutics, Inc. Press release Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations GlobeNewswire
PVLAPalvella Therapeutics, Inc. Stock news Bank of America Corp DE Has $4.73 Million Holdings in Palvella Therapeutics, Inc. $PVLA Defense World
PVLAPalvella Therapeutics, Inc. Stock news Palvella Therapeutics: First Approval Could Unlock A Rare-Disease Commercial Flywheel Seeking Alpha
See more
FAQ

Questions about Palvella Therapeutics, Inc.

What does Palvella Therapeutics, Inc. do?
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients with serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), which is in a Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as a Phase 2 clinical trial to treat cutaneous venous malformations. The company also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. Palvella Therapeutics is based in Wayne, Pennsylvania.
What is PVLA's market cap?
Palvella Therapeutics, Inc. (PVLA) is a listed stock with a live quote. The latest market cap on this page is $2.3B.
Where is Palvella Therapeutics, Inc. headquartered?
Palvella Therapeutics, Inc. is headquartered in Wayne, PA.
How do I get PVLA news from the API?
Call GET /v1/news?tickers=PVLA. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does PVLA news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for PVLA, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the PVLA price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs